ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 228 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.98 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,077,000 | +306.4% | 44,485 | +797.1% | 0.00% | +100.0% |
| Q4 2020 | $265,000 | -65.9% | 4,959 | -82.9% | 0.00% | -80.0% |
| Q1 2019 | $776,000 | +288.0% | 29,043 | +199.8% | 0.01% | +400.0% |
| Q3 2018 | $200,000 | -42.7% | 9,687 | -38.3% | 0.00% | -66.7% |
| Q1 2018 | $349,000 | -23.6% | 15,695 | -0.8% | 0.00% | -25.0% |
| Q4 2017 | $457,000 | +0.2% | 15,815 | +31.2% | 0.00% | 0.0% |
| Q3 2017 | $456,000 | +38.2% | 12,058 | +2.0% | 0.00% | +33.3% |
| Q2 2017 | $330,000 | -8.6% | 11,821 | +5.8% | 0.00% | 0.0% |
| Q1 2017 | $361,000 | +35.7% | 11,171 | +8.5% | 0.00% | 0.0% |
| Q4 2016 | $266,000 | +8.6% | 10,296 | +33.8% | 0.00% | 0.0% |
| Q3 2016 | $245,000 | +17.8% | 7,697 | +18.5% | 0.00% | 0.0% |
| Q2 2016 | $208,000 | -43.6% | 6,497 | -2.4% | 0.00% | +200.0% |
| Q1 2016 | $369,000 | +81.8% | 6,660 | +6.8% | 0.00% | -66.7% |
| Q1 2015 | $203,000 | – | 6,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |